Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 10/20 | 1.00 |
| ▸ | RARA | P10276 | 9/20 | 1.00 |
| ▸ | RARG | P13631 | 9/20 | 1.00 |
| ▸ | CYP26A1 | O43174 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 0.84 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.84 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.84 |
| ▸ | BLVRB | P30043 | 1/20 | 0.84 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.74 |
| ▸ | RXRA | P19793 | 9/20 | 0.67 |
| ▸ | RXRB | P28702 | 8/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL726740 | 1.00 | RARB (1.00) | RARBRARARARGCYP26A1CYP3A4 | |
| Tamibarotene SCHEMBL36207 | 0.91 | RARB (1.00) | RARBRARARARGCYP26A1CYP3A4 | |
| Tamibarotene SCHEMBL29373818 | 0.91 | RARB (1.00) | RARBRARARARGCYP26A1CYP3A4 | |
| Tamibarotene SCHEMBL21055743 | 0.90 | RARB (0.97) | RARBRARARARGCYP26A1CYP3A4 | |
| SCHEMBL7621355 | 0.90 | RARA (0.82) | RARBRARARARGCYP26A1CYP3A4 | |
| SCHEMBL8459704 | 0.89 | RARA (0.80) | RARBRARARARGCYP26A1CYP3A4 | |
| SCHEMBL9446527 | 0.89 | CYP26A1 (0.80) | RARBRARARARGCYP26A1CYP3A4 | |
| SCHEMBL1616078 | 0.87 | CYP26A1 (0.78) | RARBRARARARGCYP26A1CYP3A4 | |
| SCHEMBL9446600 | 0.87 | RARA (0.78) | RARBRARARARGCYP26A1CYP3A4 | |
| SCHEMBL1616121 | 0.87 | CYP26A1 (0.78) | RARBRARARARGCYP26A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-12599679-B2 | Circular RNA compositions | ORNA THERAPEUTICS, INC. (US) | 2026-04-14 | — | — | US | claimed |
| US-12589189-B2 | Use of retinoic acid receptor (RAR) agonists for reversing, preventing, or delaying calcification of aortic valve | INSERM (INSTITUTE NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE) (FR) | 2026-03-31 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| EP-4037672-B1 | RETINOIC ACID RECEPTOR (RAR) AGONISTS FOR REVERSING, PREVENTING, OR DELAYING CALCIFICATION OF AORTIC VALVE | INST NAT SANTE RECH MED (FR) | 2026-03-11 | — | — | EP | claimed |
| US-12571044-B2 | Classifier for identification of robust sepsis subtypes | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-03-10 | — | — | US | claimed |
| EP-4008728-B1 | CD70 BINDING MOLECULES AND METHODS OF USE THEREOF | KITE PHARMA INC (US) | 2025-12-17 | — | — | EP | claimed |
| US-20250339464-A1 | ENDOGENOUS SIGNALING MOLECULE ACTIVATING CHIMERIC ANTIGEN RECEPTORS AND METHODS OF GENERATION THEREOF | Miltenyi Biotec B.V. & Co. KG (DE) | 2025-11-06 | — | — | US | claimed |
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2025-11-06 | — | — | US | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| WO-2022132206-A1 | SINGLE CELL SECRETOME ANALYSIS | BECTON, DICKINSON AND COMPANY (US) | 2022-06-23 | — | — | WO | claimed |
| WO-2022125439-A2 | INNATE IMMUNE CELL SILENCING BY SIRP-ALPHA ENGAGER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-06-16 | — | — | WO | claimed |
| EP-4010082-A1 | MULTISPECIFIC ANTI-TCR DELTA VARIABLE 1 ANTIBODIES | GammaDelta Therapeutics Limited (GB) | 2022-06-15 | — | — | EP | claimed |
| US-20220178909-A1 | MULTIPLEXED SINGLE CELL IMMUNOASSAY | BECTON, DICKINSON AND COMPANY | 2022-06-09 | — | — | US | claimed |
| EP-4008728-A1 | CD70 BINDING MOLECULES AND METHODS OF USE THEREOF | Kite Pharma, Inc. (US) | 2022-06-08 | — | — | EP | claimed |
| EP-3986463-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | Hangzhou Dac Biotech Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| EP-3986476-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | Hangzhou Dac Biotech Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| WO-2022078524-A2 | SPECIFIC CONJUGATION OF AN ANTIBODY | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-04-21 | — | — | WO | claimed |
| WO-2022034562-A1 | MULTISPECIFIC ANTI-TCR DELTA VARIABLE 1 ANTIBODIES | GammaDelta Therapeutics Limited (GB) | 2022-02-17 | — | — | WO | claimed |
| CN-114040781-A | Formulation of conjugate of TUBULYSIN derivative and cell binding molecule | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599679-B2 | Circular RNA compositions | BCL6, BCL9, BCL6B | RARB 2029/4885RARA 2505/4885RARG 2489/4885 |
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | FCGR2A, FCGR3B, FCGR1A | RARB 2421/4885RARA 2105/4885RARG 1147/4885 |
| US-12589189-B2 | Use of retinoic acid receptor (RAR) agonists for reversing, preventing, or delaying calcification of aortic valve | RARB, RARA, RXRB | RARB 1/4885RARA 2/4885RARG 4/4885 |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | CD4, TAP1, MCTS1 | RARB 2779/4885RARA 3019/4885RARG 2579/4885 |
| US-12571044-B2 | Classifier for identification of robust sepsis subtypes | LITAF, CD14, MYADM | RARB 3477/4885RARA 4709/4885RARG 4573/4885 |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | WNT3A, GSK3B, GSK3A | RARB 70/4885RARA 354/4885RARG 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.